Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. In our lead programs, we are developing multiple product candidates that target the insulin-like growth factor-1 receptor (IGF-1R) to treat patients who suffer from thyroid eye disease (TED), a debilitating auto-immune disease.
Learn more about Viridian and our programs in our corporate presentation.
Recent Press Releases
- Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration
- Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association
- Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares